Revenue → Gross profit: $58.6BPharmaceutical → Revenue: $54.8BMedical devices → Revenue: $30.4BRevenue → Cost of revenue: $26.6BDiscontinued operations → Net profit: $21.8BGross profit → SG&A: $21.5BImmunology → Pharmaceutical: $18.1BOncology → Pharmaceutical: $17.7BGross profit → R&D: $15.1BGross profit → Operating profit: $15.1BOperating profit → Net profit: $13.3BSurgery → Medical devices: $10.0BOrthopaedics → Medical devices: $8.9BNeuroscience → Pharmaceutical: $7.1BGross profit → Other: $6.6BInterventional → Medical devices: $6.3BVision → Medical devices: $5.1BInfectious diseases → Pharmaceutical: $4.4BPulmonary → Pharmaceutical: $3.8BOther pharma → Pharmaceutical: $3.7BOperating profit → Tax: $1.7BGross profit → Restructuring: $0.5BInterest income → Gross profit: $0.5BGross profit → In-process R&D: $0.3BImmunology: $18.1BPharmaceutical: $54.8BInfectious diseases: $4.4BNeuroscience: $7.1BOncology: $17.7BPulmonary: $3.8BOther pharma: $3.7BRevenue: $85.2BMedical devices: $30.4BInterventional: $6.3BOrthopaedics: $8.9BSurgery: $10.0BVision: $5.1BGross profit: $59.1BCost of revenue: $26.6BOperating profit: $15.1BSG&A: $21.5BR&D: $15.1BIn-process R&D: $0.3BRestructuring: $0.5BOther: $6.6BTax: $1.7BNet profit: $35.2BInterest income: $0.5BDiscontinued operations: $21.8Bcreated with SankeyArt.comImmunology$18.1BPharmaceutical$54.8B4% Y/YInfectious diseases$4.4BNeuroscience$7.1BOncology$17.7BPulmonary$3.8BOther pharma$3.7BRevenue$85.2B6% Y/YMedical devices$30.4B11% Y/YInterventional$6.3BOrthopaedics$8.9BSurgery$10.0BVision$5.1BGross profit$59.1B6% Y/YCost of revenue$26.6B8% Y/YOperating profit$15.1B-22% Y/YSG&A$21.5B6% Y/YR&D$15.1B7% Y/YIn-process R&D$0.3B-60% Y/YRestructuring$0.5B78% Y/YOther$6.6B719% Y/YTax$1.7B-42% Y/YNet profit$35.2BInterest income$0.5B129% Y/YDiscontinued operations$21.8BJohnson & Johnson FY23 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3